Robert Renninger net worth and biography

Robert Renninger Biography and Net Worth

CFO of Athira Pharma

Robert joined LeonaBio in 2020 and has served in his current role since February 2025. Prior to that, he held the roles of Vice President of Finance, Senior Director of Finance and Director of Finance. Before coming to LeonaBio, Robert served as financial controller of Infobip (formerly OpenMarket), a global communications platform. He also served as technical controller of Baker Hughes, an energy company, and served in various roles at Ernst & Young, LLP, a global accounting firm. Robert received his Master of accounting from the University of Michigan and his B.A. in accounting from Seattle University.

What is Robert Renninger's net worth?: The estimated net worth of Robert Renninger is at least $93.44 thousand as of March 4th, 2026. Renninger owns 15,851 shares of Athira Pharma stock worth more than $93,442 as of September 23rd. This net worth evaluation does not reflect any other assets that Renninger may own. Learn More about Robert Renninger's net worth.
How do I contact Robert Renninger?: The corporate mailing address for Renninger and other Athira Pharma executives is 18706 North Creek Parkway, Suite 104, Bothell, WA, 98011. Athira Pharma can also be reached via phone at 425-620-8501 and via email at [email protected]. Learn More on Robert Renninger's contact information.
Has Robert Renninger been buying or selling shares of Athira Pharma?: Robert Renninger has not been actively trading shares of Athira Pharma over the course of the past ninety days. Most recently, Robert Renninger sold 906 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a transaction totalling $4,865.22. Following the completion of the sale, the chief financial officer now directly owns 15,851 shares of the company's stock, valued at $85,119.87. Learn More on Robert Renninger's trading history.
Who are Athira Pharma's active insiders?: Athira Pharma's insider roster includes Mark Litton (CEO), Robert Renninger (CFO), Martin San (Insider), and Mark Worthington (General Counsel). Learn More on Athira Pharma's active insiders.
Are insiders buying or selling shares of Athira Pharma?: In the last twelve months, insiders at the sold shares 8 times. They sold a total of 14,513 shares worth more than $86,093.34. The most recent insider tranaction occured on March, 4th when insider Martin Javier San sold 1,720 shares worth more than $9,236.40. Insiders at Athira Pharma own 25.7% of the company. Learn More about insider trades at Athira Pharma.
Information on this page was last updated on 3/4/2026.

Robert Renninger Insider Trading History at Athira Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2026	Sell	906	$5.37	$4,865.22	15,851
1/2/2026	Sell	297	$6.88	$2,043.36	12,857
7/1/2025	Sell	289	$2.90	$838.10	10,918
1/2/2025	Sell	288	$5.60	$1,612.80	8,972

Robert Renninger Buying and Selling Activity at Athira Pharma

Athira Pharma Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $5.89

$5.69

$6.35

50 Day Range

MA: $7.50

$6.05

$8.53

2 Week Range

Now: $5.89

$3.60

$14.21

Volume

21,384 shs

Average Volume

52,104 shs

Market Capitalization

$55.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05